Table 2.
Clinical features of patients with essential thrombocythemia and polycythemia vera who developed myelofibrosis.
| ET (N=10) | PV (N=11) | ||||||
|---|---|---|---|---|---|---|---|
| At ET diagnosis | At SMF diagnosis | P a) | At PV diagnosis | At SMF diagnosis | P a) | ||
| Age (yr), median (range) | 62 (51–75) | 70 (63–83) | 61 (36–75) | 73 (52–85) | |||
| Palpable splenomegaly, N (%) | 0 (0.0) | 6 (60.0) | <0.001 | 4 (36.4) | 5 (45.5) | 1.000 | |
| Laboratory findings | |||||||
| WBC, ×109/L | 7.0±6.0 | 8.6±6.1 | 0.101 | 15.1±7.7 | 20.9±21.7 | 0.384 | |
| Monocyte, ×109/L | 0.8±0.4 | 0.4±0.5 | 0.118 | 1.1±0.6 | 1.6±2.3 | 0.598 | |
| Hemoglobin, g/dL | 12.9±2.5 | 8.9±1.5 | 0.001 | 17.3±3.1 | 10.6±1.4 | 0.001 | |
| Platelet, ×109/L | 667.0±845.7 | 527.8±486.8 | 0.033 | 626.7±426.3 | 399.3±401.2 | 0.154 | |
| Leukoerythroblastosis, N (%) | 0 (0.0) | 8 (80.0) | <0.001 | 0 (0.0) | 10 (90.9) | <0.001 | |
| LDH, ×UNL | 1.3±0.6 | 2.8±1.2 | 0.004 | 1.1±1.1 | 2.2±0.6 | 0.037 | |
| Abnormal karyotype, N (%) | 0 (0.0) | 3 (30.0) | <0.001 | 2 (18.2) | 6 (54.5) | 0.076 | |
a)Data presented as mean±SD were analyzed using Student’s t-test for paired samples; data presented as percentages were analyzed using the chi-square test.
Abbreviations: ET, essential thrombocythemia; LDH, lactate dehydrogenase; SMF, secondary myelofibrosis; UNL, upper normal limit.